Evidence map›Paper›PMID 41999482›Full record

ReviewCurrent atherosclerosis reports2026

Lp(a) at the Crossroads: New Strategies to Reduce Residual Cardiovascular Risk.

Vaidehi Kaushal, Preneet C Brar, Brenda Kohn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Vaidehi KaushalDivision of Pediatric Endocrinology and Diabetes, Department of Pediatrics, NYU Grossman School of Medicine, NYU-Langone Health, New York City, NY, USA.
Preneet C BrarDivision of Pediatric Endocrinology and Diabetes, Department of Pediatrics, NYU Grossman School of Medicine, NYU-Langone Health, New York City, NY, USA.
Brenda KohnDivision of Pediatric Endocrinology and Diabetes, Department of Pediatrics, NYU Grossman School of Medicine, NYU-Langone Health, New York City, NY, USA. Brenda.Kohn@nyulangone.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewLipoprotein(a) [Lp(a)] is an increasingly recognized, genetically determined contributor to cardiovascular risk, implicated in both atherosclerotic cardiovascular disease and aortic valve stenosis. At present, several emerging therapies specifically targeting Lp(a) are under development. RECENT

findingsGiven the high prevalence of elevated Lp(a) levels in the general population, major cardiovascular societies now recommend at least one lifetime measurement in all high risk adults. While no approved treatments currently exist, several novel Lp(a) lowering therapies are in advanced stages of clinical development and show considerable promise. This review outlines the biological and genetic basis of Lp(a), examines itsassociation with diverse cardiovascular diseases, and highlights emergingtherapeutic strategies that may significantly influence future clinical management.

Indexed as

AtherosclerosisCardiovascular DiseasesLipoprotein(a)Heart Disease Risk FactorsHumansHypolipidemic AgentsRisk FactorsHypolipidemic AgentsLipoprotein(a)AtherosclerosisCardiac risk factorLp(a)Novel therapies

Identifiers

PMID41999482

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.